These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12597158)

  • 61. Using biomarkers in drug development.
    Workman P
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):736-9. PubMed ID: 17099630
    [No Abstract]   [Full Text] [Related]  

  • 62. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
    Lin F; Li Z; Hua Y; Lim YP
    Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hypoxia-inducible factor-1 as a therapeutic target in cancer.
    Tang CM; Yu J
    J Gastroenterol Hepatol; 2013 Mar; 28(3):401-5. PubMed ID: 23173651
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ectokinases as novel cancer markers and drug targets in cancer therapy.
    Yalak G; Vogel V
    Cancer Med; 2015 Mar; 4(3):404-14. PubMed ID: 25504773
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
    Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
    Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Folate receptor-mediated drug targeting: from therapeutics to diagnostics.
    Hilgenbrink AR; Low PS
    J Pharm Sci; 2005 Oct; 94(10):2135-46. PubMed ID: 16136558
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Validation of analytic methods for biomarkers used in drug development.
    Chau CH; Rixe O; McLeod H; Figg WD
    Clin Cancer Res; 2008 Oct; 14(19):5967-76. PubMed ID: 18829475
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
    Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
    Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 71. NMR-based metabolomics: translational application and treatment of cancer.
    Serkova NJ; Spratlin JL; Eckhardt SG
    Curr Opin Mol Ther; 2007 Dec; 9(6):572-85. PubMed ID: 18041668
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
    Rubio-Viqueira B; Hidalgo M
    Clin Pharmacol Ther; 2009 Feb; 85(2):217-21. PubMed ID: 19005462
    [No Abstract]   [Full Text] [Related]  

  • 73. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer.
    Amin S; Bathe OF
    BMC Cancer; 2016 Nov; 16(1):850. PubMed ID: 27814715
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 75. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.
    Indovina P; Pentimalli F; Casini N; Vocca I; Giordano A
    Oncotarget; 2015 Jul; 6(20):17873-90. PubMed ID: 26160835
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 4.